Oncothermia and the use of oral transmucosal fentanyl citrate
Dr. Lee’s team, Department of Oncology, Institute of Clinical Medicine, Chonbuk University, Jeonju, Republic of Korea, published in the journal Clin Ther. 2016 Dec; 38 (12): 2548-2554, results on the safety of the use of Oncothermia and the drug for pain: transmucosal oral fentanyl citrate.
The purpose of this study was to determine if changes occur in the absorption and disposition of the drug fentanyl when it is administered together with the modulated electrohyperthermia treatment (mEHT, Oncothermia).
A randomized, single-dose, crossover, open-label study was used to investigate the effect of Oncothermia on the pharmacokinetic properties of fentanyl in 12 healthy volunteers.
Method
The 12 healthy volunteers were each administered a single dose of oral transmucosal fentanyl citrate (OTFC) or a single dose of OTFC with Oncothermia. Oncothermia was performed on the abdomen for 1 hour. Blood samples were collected for 24 hours after dosing. The temperature of the abdominal skin surface was assessed before dosing and at 10, 20, and 60 minutes after dosing.
Results
There was an increase in the overall exposure to the drug without implications of any clinical significance. OTFC can be administered without limitations in combination with Oncothermia, and it is not necessary to modify the dosing regimen.
For further information on Oncothermia, please visit the following link.
